GlassScriptPhysician profile
Raz Khavari
NPI 1912020785
$7,650.24
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,057 · 2020: $2,098 · 2021: $1,681 · 2022: $1,578 · 2023: $133 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,761.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $801.60 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $494.26 | 2019-2021 | |
| Janssen Biotech, INC. | $493.07 | 2019-2022 | |
| Abbvie INC. | $488.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $461.25 | 2020-2022 | |
| Radius Health, INC. | $432.20 | 2019-2022 | |
| Horizon Therapeutics Plc | $336.16 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $327.09 | 2020-2022 | |
| Lilly USA, LLC | $322.87 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $266.67 | 2021-2022 | |
| Genentech USA, INC. | $252.25 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $224.29 | 2023-2024 | Dupixent |
| Ucb, INC. | $187.79 | 2022-2023 | Cimzia |
| Mallinckrodt Enterprises LLC | $176.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 110 LLC | $100.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.71 | 2019-2022 | |
| Celgene Corporation | $84.26 | 2019 | |
| Merck Sharp & Dohme LLC | $67.57 | 2019-2021 | |
| Genzyme Corporation | $64.93 | 2020 | |
| Genentech, INC. | $49.95 | 2021 | |
| Sobi, INC | $37.59 | 2021-2022 | |
| Pfizer INC. | $34.08 | 2019 | |
| Bioventus LLC | $32.19 | 2022 | |
| Aurinia Pharma U.S., INC. | $29.04 | 2022 | |
| Organon LLC | $17.90 | 2021 | |
| Antares Pharma, INC. | $17.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raz Khavari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.